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Fibroblast growth factors (FGFs) play diverse roles in several developmental processes. Mutations leading to deregulated FGF signaling
can cause human skeletal dysplasias and cancer.1,2 Here we report a missense mutation (Ser99Asp) in exon 2 of FGF9 in 12 patients with
multiple synostoses syndrome (SYNS) in a large Chinese family. In vitro studies demonstrate that FGF9S99N is expressed and secreted as
efﬁciently as wild-type FGF9 in transfected cells. However, FGF9S99N induces compromised chondrocyte proliferation and differentia-
tion, which is accompanied by enhanced osteogenic differentiation and matrix mineralization of bone marrow-derived mesenchymal
stem cells (BMSCs). Biochemical analysis reveals that S99Nmutation in FGF9 leads to signiﬁcantly impaired FGF signaling, as evidenced
by diminished activity of Erk1/2 pathway and decreased b-catenin and c-Myc expression when compared with wild-type FGF9. Impor-
tantly, the binding of FGF9S99N to its receptor is severely impaired although the dimerization ability of mutant FGF9 itself or with wild-
type FGF9 is not detectably affected, providing a basis for the defective FGFR signaling. Collectively, our data demonstrate a previously
uncharacterized mutation in FGF9 as one of the causes of SYNS, implicating an important role of FGF9 in normal joint development.Introduction
Multiple synostoses syndrome (SYNS) is an autosomal-
dominant disorder characterized by the joint fusions that
commonly involve proximal interphalangeal, carpal-
tarsal, humeroradial, and cervical spine joints. A subpopu-
lation of patients also manifests characteristic facies and
progressive conductive deafness due to fusion of the ossi-
cles. Previous studies revealed that the mutations in NOG
(MIM 602991) on chromosome 17q22 and growth differ-
entiation factor-5 (GDF5 [MIM 601146]) on chromosome
20q11.2 are responsible for multiple synostoses syndrome
(SYNS1 [MIM 186500], SYNS2 [MIM 610017], respec-
tively).3,4 NOG encodes a secreted protein, Noggin, that
is involved in developmental processes, including the
regulation of chondrogenesis in somites and limb buds,
where it acts as an antagonist to the bone morphogenetic
proteins (BMPs).5–7 It has been shown that mutations in
NOG not only cause SYNS1 but also lead to proximal sym-
phalangism (SYM1 [MIM 185800]) and tarsal-carpal coali-
tion syndrome (TCC [MIM 186570]),3,8,9 diseases with
clinical features similar to SYNS1. GDF5, also known as
cartilage-derived morphogenetic protein 1 (CDMP1), is
a secreted growth factor expressed during the course of
skeletal development and belongs to TGF-b superfamilies.
The mutations in GDF5 in both mouse and human are
known to cause abnormal joint development.10–12ThHere, we report a ﬁve-generation family with common
features of SYNS from Qinghai Province, China. The 12
affected individuals in this pedigree display the fusions
of proximal interphalangeal, carpal-tarsal, and humerora-
dial joints. Unexpectedly, linkage analysis and sequencing
results indicated that the disease phenotype was associated
with neitherNOGnorGDF5mutations. Instead, amissense
mutation in ﬁbroblast growth factor 9 was identiﬁed in all
affected individuals. Thus, our study identiﬁed FGF9 as the
third disease-causing gene for SYNS phenotype, impli-
cating a crucial role of FGF9 in human joint development.
Subjects and Methods
Human Subjects
A ﬁve-generation family with autosomal-dominant SYNS was
ascertained through initial identiﬁcation of a proband (IV-9 in
Figure 1) from Qinghai Province, China. Approval for this study
was obtained from the committee of Shanghai Second Medical
University (SHSMU) charged with reviewing ethics. After informed
consent was signed, all affected individuals and family members
who agreed to participate in this study were evaluated by experi-
enced orthopedists and radiologists. The diagnosis was made on
the basis of family history and physical and radiographic examina-
tions on elbows, hands, feet, and cervical and lumbar spines. The
conductive hearing was evaluated by tuning fork test. Peripheral
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Figure 1. A Chinese Pedigree with Autosomal-Dominant SYNS
(A) SYNS pedigree. Squares, circles, and slashed-through symbols indicate males, females, and individuals known to be deceased, respec-
tively. Affected individuals are indicated by black symbols. Arrow marks the proband with SYNS in this pedigree (IV-9).
(B and C) Right elbow photograph (B) and radiograph (C) of individual IV-12 show typical humeroradial synostoses. Arrows indicate the
inability to ﬂex the right elbow joint.
(D) Left-foot radiograph of individual IV-12 shows the synostoses among ﬁrst metatarsal, cuneiform, and navicular (arrows).
(E) Right-hand radiograph of individual IV-9 displays the synostoses of interphalangeal joints in the ﬁfth digit (arrows).
(F) Lumbar-spine radiograph of individual IV-9 shows the synostoses of lumbar joints at L2-3 and L4-5 (arrows).from all family members with QIAamp DNA blood mini kit
(QIAGEN). The control DNA samples used for assessing the
frequency of DNA sequence alterations in the population were ob-
tained from250normal, unrelated, ethnicallymatched individuals.
Genome-wide Scan and Mutation Analysis
The genotypes of the family members were determined by using
the microsatellites from Applied Biosystems Prism Linkage
Mapping Set Version 2 according to the manufacturer’s instruc-
tions on a MegaBACE sequencer. Genetic Proﬁler (version 1.1)
was used for genotype assignment, and MLINK program from
the LINKAGE 5.1 computer program package was used for two-
point linkage analysis.13 Cyrillic (version 2.0) was used for haplo-
type analysis. For mutation detection, we performed PCR with the
PCR product presequencing kit (USB), puriﬁed appropriate PCR
products, and sequenced them with dye-primer chemistry
(Applied Biosystems) on an ABI 377 automated sequence analyzer
(Applied Biosystems). The resulting sequences were analyzed with
the Sequencher sequence alignment program (ACGT codes). The
primers used for mutation detection are listed in the Supplemental
Data available online.54 The American Journal of Human Genetics 85, 53–63, July 10, 200Cell Culture and Transfection
COS-7 or 293T cell lines used for expression and secretion tests
were grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM), sup-
plemented with 10% heat-inactivated fetal calf serum, 100 units/
ml penicillin, and 100 mg/ml streptomycin. Cells were transfected
with Flag-tagged plasmids encoding either wild-type or mutant
FGF9, and empty vector by using LipofectAMINE 2000 (Invitro-
gen). Cell lysates were prepared and culture media were collected
48 hr after transfection. The conditional media composed of
normal complete medium and transfected cell cultured medium
(volume 1:1) were used for subsequent experiments.
Cell Differentiation Assays
Rat calvaria chondrogenic cell line (RCJ 3.1 C5.18 cells) was main-
tained in a-MEM supplemented with 15% heat-inactivated fetal
calf serum, 100 units/ml penicillin, 100 mg/ml streptomycin, 2mM
sodium pyruvate (GIBCO BRL), and 107 M dexamethasone. The
conﬂuenced cells were further cultured with conditional medium
containing FGF9 or FGF9S99N in the presence of 50 mg/ml ascorbic
acid phosphate, 10 mM b-glycerophosphate (Sigma), and heparin
(2 mg/ml). Chondrocyte differentiation was assessed by alcian9
blue staining as previously reported.14 For quantiﬁcation of the
chondrocyte staining, cells were solubilized in 1% SDS by shaking
for 30 min at room temperature. Absorbances were taken at
605 nm for triplicate samples.Mouse bonemarrow-derivedmesen-
chymal stem cells (BMSCs) were induced to osteoblastic differenti-
ation under the same condition as mentioned above. The osteo-
blastic phenotype was assessed by alkaline phosphatase (ALP)
staining. Cells were ﬁxed with 4% paraformaldehyde for 10 min
at 4C, washed with 0.056 M 2-amino-2-methylpropanol (AMP;
Sigma) buffer and stainedwith substrate solution (0.5mg/mlnaph-
thol AS-MX phosphate and 0.5 mg/ml Fast Red Violet LB salt in
0.056 M AMP buffer) for 5 min, and the reaction was stopped
withTEbuffer. Thematrixmineralizationwas visualizedby alizarin
red staining.15 Cells were washed and ﬁxed as mentioned above.
After ﬁxation, the cell layers were washed with PBS and stained
with 1% alizarin red S (Sigma) in 0.1% NH4OH (pH 6.5) for
2 min. The cell layers were washed with H2O and then observed
and photographed with an Olympus CKX41 microscope.
mRNA and Protein Assays
Total RNA was extracted from the cultures at the indicated
time, with the Trizol reagent RNA extraction protocol according
to the manufacturer’s instructions (Invitrogen). Semiquantitative
RT-PCR was performed with cDNA reverse transcribed from 1 mg
of total RNA. PCR cycles varied from 20 to 37 cycles. For pro-
tein-blot analysis, cell cultures were lysed in RIPA buffer contain-
ing a protease inhibitor cocktail (Sigma). Culture media of DNA-
transfected cells were incubated with heparin-sepharose beads
overnight at 4C. The beads were washed twice with phosphate-
buffered saline (PBS) and suspended in Laemmli buffer. The eluted
or cell lysate proteins were separated by SDS-PAGE (12.5% gels)
and blotted with the antibodies indicated.
GST Pull-Down Assay
GST-FGF9 fusion proteins were extracted and immobilized on
glutathione-sepharose beads by incubation of the puriﬁed GST-
protein fusions with glutathione-sepharose beads. 293T cells
were transiently transfected with Flag-FGF9, Flag-FGF9S99N, and
empty vector. Cell lysates and culture media were subjected to
incubation with GST-FGF9 sepharose for 4 hr at 4C. Precipitates
from lysates and media were separated by SDS-PAGE, transferred
to nitrocellulose membranes, and probed with the indicated anti-
bodies. Whole-cell lysates and media were blotted with Flag and
a-tubulin antibodies as the input controls. All antibodies used in
this study are listed in the Supplemental Data.
Statistics
Results are presented as means 5 standard deviation (SD). The
statistical differences were analyzedwith Student’s t test. Statistical
signiﬁcance was assumed for p < 0.05.
Results
Clinical Phenotype in Patients with SYNS in a Qinghai
Family
Twelve affected individuals in this pedigree were diagnosed
as SYNS on the basis of their clinical history and physical
and radiographic ﬁndings (Figure 1A). The individual IV-
12 manifested typical humeroradial synostoses at the right
elbow joint (Figures 1B and 1C) and semidislocation at theThleft elbow joint, which was accompanied by the synostoses
among ﬁrst metatarsal, cuneiform, and navicular (Fig-
ure 1D). The proband (IV-9, female, 37 years old) showed
the typical SYNS features such as humeroradial synostoses
and cubitus valgus at the elbows, coupled with the synos-
toses at the interphalangeal joints in the ﬁfth digit, fusions
among ﬁrst metatarsal, cuneiform, and navicular, and the
fusions of lumbar joints at L2-3 and L4-5 (Figures 1E and
1F). The other affected individuals (age 5–68, 8 men and 2
women) showed variable clinical features. The individuals
II-5, III-1, III-5, III-8, III-14, and IV-6 manifested semidislo-
cation and cubitus valgus at the elbows. They also had
synostoses between ﬁrst metacarpal and trapezium, or
synostoses among ﬁrst metatarsal, cuneiform, and navic-
ular. The individuals IV-22, IV-23, V-4, and V-6 at the age
of 11 or below displayed mild semidislocation or cubitus
valgus at elbow joints and limitation of ﬁnger joint ﬂexion,
suggesting that the SYNS phenotype is age dependent. In
addition to the proband IV-9, individuals IV-6 and V-6
had the synostosesof lumbar joints at L4-5 andL3-4, respec-
tively. The joint abnormalities in 12 affected individuals are
summarized in Table 1. The hearing, stature, and intelli-
gence were normal in all affected individuals.
Association of SYNS Phenotype in This Pedigree with
neither NOG nor GDF5 Mutation
To examine whether SYNS in this large family was due to
the mutations in either NOG or GDF5, we performed
Table 1. Phenotype Variability of Individuals Affected with SYNS
by X-Ray Examination
Affected
Individual
Age
(years) Sex
Anomaly
at Elbow
Jointa
Synostosis
at Handsb
Synostosis
at Feetc
Synostosis
at Lumbar
II-5 68 M þ þ þþ 
III-1 54 M þ  þþ 
III-5 38 M þ þ þþ 
III-8 62 F þ þþ þþ 
III-14 37 M þ þ þþ 
IV-6 16 F þ þ þþ L4-5
IV-9 37 F þþ þ þþ L2-3, L4-5
IV-12 29 M þþ þ þþ 
IV-22 11 M þ þ/  
IV-23 6 M þ þ/  
V-4 11 M þ/ þ/  
V-6 5 M þ   L3-4
a þ, mild elbow abnormalities, e.g., cubitus valgus and semi-dislocation. þþ,
severe elbow abnormality, e.g., humeroradial synostosis. þ/, cubitus valgus
or other elbow abnormalities.
b þ, the synostosis involved first metacarpal and trapezium or fifth interphalan-
geal joints. þþ, the synostosis involved first metacarpal and trapezium, plus
fifth interphalangeal joints. þ/, the synostosis trend involved fifth interphan-
geal joints.
c þþ, the synostosis involved first metatarsal, cuneiform, and navicular. , no
synostosis or other abnormalities.e American Journal of Human Genetics 85, 53–63, July 10, 2009 55
Table 2. The LOD Scores of Two-Point Linkage Analysis from Fine Mapping on Chromosome 13
Lod Score (Z) at Recombination Fraction (q)
Marker 0.0 0.1 0.2 0.3 0.4 0.5
D13S175 1.464375 3.107013 2.612414 1.857932 0.919577 0.000000
D13S1236 3.700658 3.873736 3.184450 2.259354 1.158830 0.000000
D13S1275 0.543834 2.798210 2.485964 1.817558 0.921112 0.000000
D13S1243 0.362458 2.059668 1.913292 1.429418 0.760590 0.000000
D13S221 0.429933 3.706325 3.166717 2.255349 1.121422 0.000000
D13S1254 2.907339 0.116978 0.340966 0.286847 0.113492 0.000000
D13S217 9.250479 0.011491 0.578008 0.609531 0.379275 0.000000linkage analysis by using genetic markers from chromo-
some 17q22 and 20q11.2, respectively. Unexpectedly, no
linkage with either of the two genes was detected
(Table S1). To exclude the possibility that SYNS in this
family is caused by two independently segregating muta-
tions in NOG and GDF5, we also sequenced the coding
regions and ﬂanking introns of these two genes in three
affected individuals and did not ﬁnd any mutations. These
data suggest that a mutation in a gene other than NOG or
GDF5 is responsible for the SYNS observed in this family.
FGF9 S99N Mutation as a Genetic Alteration in SYNS
To search for such genetic alterations, we performed a
genome-wide screen and identiﬁed a single locus on chro-
mosome 13q11-q12 that cosegregated with the disease.
The maximum two-point LOD score was 3.7 at D13S1236
(q ¼ 0.0). Fine mapping and haplotype analysis narrowed
the critical interval to 8.6 Mb between D13S175 and
D13S221 (Table 2 and Figure S1).
Based on a human genome database, it is known that 22
candidate genes are located in this region. Among them,
ﬁbroblast growth factor 9 (FGF9, [MIM 600921]) seems to
be one of themost attractive candidate genes because avail-
able information indicates that mammalian FGFs control
a wide spectrum of biological functions during develop-
ment and adult life,16 and deregulated FGF signaling is
closely associated with human diseases including craniosy-
nostoses and skeletal dysplasia syndromes.17 Moreover,
previous studies have showed that FGF9 can induce endo-
chondral ossiﬁcation in cranial mesenchyme and regulate
early hypertrophic chondrocyte differentiation and skeletal
vascularization in the developing stylopod.18 Thus, we
focused on FGF9 to search for potential mutations. FGF9
localizes at chromosome 13q12, the region between
D13S175 and D13S1236 (Figure 2A). It has three exons
with an open reading frame of 624 bp, encoding a peptide
of 208 amino acids (Figure 2B). By analyzing the sequences
of PCR products ampliﬁed from each FGF9 exon, we were
able to identify a heterozygous mutation of G-to-A transi-
tion at nucleotide position 296 within exon 2, leading to
an amino acid change from serine (AGT) to asparagine
(AAT) at the 99th amino acid residue (Figures 2C and 2D).56 The American Journal of Human Genetics 85, 53–63, July 10, 20Signiﬁcantly, the exact G-to-A mutation was detected in
all 12affected, butnot inunaffected,members in the family.
In addition, we screened 250 unrelated, ethnicallymatched
individuals (i.e., 500 chromosomes) and found no such
mutation in FGF9 exon 2 (data not shown). Thus, our study
has identiﬁed the FGF9 S99N mutation as a genetic alter-
ation that cosegregateswithmultiple synostoses syndrome.
To gain insight into this FGF9 mutation, we performed
a computer simulation of the structure of the FGF9 protein
with Molscript software. The result predicts that FGF9 3D
structure and its binding to the receptor may be altered
because of S99N mutation (Figure 2E), suggesting it as
a consequential mutation.
Normal Expression and Secretion of FGF9S99N
When Expressed in Cells
Structurally, FGF9 does not have a typical secretory signal
peptide. Its secretion is known to be mediated via a hydro-
phobic region containing a highly conserved EFISIA motif
and a noncleaved signal sequence consisting of the ﬁrst 33
residues.19,20 A previous report showed that artiﬁcial I98N,
I100N, and A101N mutations in the FGF9 EFISIA motif
can signiﬁcantly change local hydrophobicity and interfere
with FGF9 secretion.21 These ﬁndings raised the possibility
that S99N mutation could interfere with FGF9 secretion.
Therefore, we transfected COS-7 or 293T cells with Flag-
tagged wild-type (WT) or mutant FGF9-expressing con-
struct. The expression and secretion of WTor mutant FGF9
in cell lysate and culturemediumweremeasured bywestern
blotting with an anti-Flag antibody. There were no detect-
able differences in the amount of WT and mutant FGF9
proteins found in cell lysate and medium, respectively (Fig-
ure 3A), indicative of normal expression and secretion of
mutant protein. The result is in linewith the fact that substi-
tution of serine (0.80) with asparagine (3.50) in FGF9
does not signiﬁcantly alter its hydrophobicity in Kyte-Doo-
little scale (Figure S2),22which is critical for FGF9secretion.21
Abnormal Cell Proliferation and Differentiation
Associated with FGF9S99N
To examine a potential functional consequence to this FGF9
mutation, we determined FGF9-mediated cellular effects.09
Figure 2. Identification of S99N Mutation in the Core Region of FGF9
(A) Physical map of the region between genetic marker D13S175 and D13S217. The red line indicates FGF9 locus. The black lines show
the physical distances (upper) and genetic markers (lower). This map is based on human genomic sequence NM_002010.1.
(B) Illustration of the exon-intron structure of FGF9. The exons marked as red boxes are numbered as exon 1, 2, and 3 and encode amino
acids 1–93, 94–127, and 128–208 (gray, upper), respectively. The core region of FGF9 marked as blue (lower) spans from amino acid 60
to 191.
(C) Amino acid sequence from amino acid 85 to 110 in homologs of FGF9 aligned by BLAST. Red characters indicate the highly
conserved motif (EFISIA) between amino acid 96 and 101 of FGF9. Ser99Asn mutation is indicated by an arrow.
(D) Sequence chromatograms of FGF9mutation. Left and right diagrams show normal and mutation sequence, respectively. The muta-
tion site (G > A) is indicated (arrows).
(E) 3D structure of FGF9-FGFR3c complex modeled with Molscript software. Red and green ribbons indicate FGF9 and FGFR3c, respec-
tively. Upper diagram shows wild-type FGF9 binding to FGFR3c and lower diagram shows potential binding and structural alteration of
mutant FGF9 and FGFR3c. The substituted residue is indicated by arrows.FGF signaling is involved in multiple cellular processes,
including cell growth, differentiation, migration, and
survival depending on the cellular context.23 We collected
the culture medium from cells expressing either WT or
mutant FGF9 and assessed their activity on chondrocyte
proliferation and differentiation. Consistent with previ-
ously reports,14 conditioned medium containing FGF9
promoted cell proliferation of rat calvaria chondrogenic
cell line (RCJ 3.1 C5.18 cells) (Figure 3B), as well as mouse
primary chondrocytes (Figure S3A). In contrast, no such
effect was observed when FGF9S99N-containing medium
was used, suggesting that S99N mutation compromised
FGF9 to promote chondrogenic cell proliferation. By using
in vitro RCJ cell culture model for chondrocyte differentia-
tion, we also evaluated the ability of mutant FGF9 to inﬂu-Thence cell differentiation. We found that WT FGF9 induced
chondrocyte differentiation, evidenced by increased alcian
blue staining after 7 day culture. However, chondrocyte
differentiation induced by FGF9S99N remained at a compa-
rable level with control cells (Figure 3C). The expression
levels of type II collagen 1 (COL2A1) gene, a well-character-
ized, speciﬁc marker of commitment to the chondrogenic
lineage, and ALP, the most widely recognized biochemical
marker for osteoblast activity, were analyzed by semiquanti-
tative RT-PCR. The alteration of COL2A1 expression was
found to be consistentwith the result of alcian blue staining
(Figure 3D). Meanwhile, a decreased expression upon WT
FGF9 treatment and unchanged expression of ALP were
observed when compared to control (Figure 3D), suggesting
that FGF9 mutant is unable to exert an inhibitory effect one American Journal of Human Genetics 85, 53–63, July 10, 2009 57
Figure 3. Abnormal Cell Proliferation and Differentiation Induced by FGF9S99N
(A) Expression and secretion of FGF9S99N by transfected cells. FGF9S99N in medium was detected at the level comparable to wild-type
FGF9.
(B) RCJ cell proliferation was assayed by MTT colorimetric method in quadruplicate at the time points indicated. The data shown are
representative of at least four independent experiments. * indicates p < 0.05; ** indicates p < 0.01 (WT versus mutant).
(C) RCJ cells were differentiated to chondrocytes in conditional medium for the indicated time. The chondrocytes were stained with
alcian blue and, after solubilization, absorbances were taken at 605 nm in triplicate. The representative of three independent experi-
ments is shown. ** indicates p < 0.01 (WT versus mutant).
(D) RCJ cells were differentiated to chondrocytes in conditional medium and cell cultures were lysed and total RNA was extracted at the
indicated time. The expression levels of COL2A1 (for chondrocytes) and ALP (for osteoblasts) were assayed by semiquantitative RT-PCR.
b-actin was shown as inner control. For osteoblastic differentiation, BMSCs were differentiated to osteoblasts in conditional medium for
7 days and 10 days.
(E and F) Cell cultures were stained with naphthol AS-MX phosphate for ALP activity (E) and alizarin red S for matrix mineralization
(F, images of day 7). The photographs were taken under Olympus CKX41 microscope (magniﬁcation, 103).osteoblastic differentiation as WT FGF9 does. For further
evaluation of the effect of FGF9 on osteogenic differentia-
tion, BMSCs were used as a model system because it is well
documented that BMSCs can be directed toward the osteo-
genic lineage in vitro when they are treatedwith dexameth-
asone, b-glycerophosphate, and ascorbic acid. With cell
differentiation in the presence of either WT FGF9 or
FGF9S99N, osteoblast activitywas visualizedbyALP substrate
staining.The results indicated thatWTFGF9exerts an inhib-
itory effect on osteogenic differentiation, whereas FGF9S99N
has no such effect. ALP activity remains unchanged when
compared to control cells (Figure 3E). Furthermore, extracel-58 The American Journal of Human Genetics 85, 53–63, July 10, 20lularmatrix calciﬁcationwas detected by alizarin red S stain-
ing at days 7 and 10. As a consequence of changes in ALP
expression and activity, similar results were observed in
the extracellular matrix calciﬁcation upon WT FGF9 or
FGF9S99N treatment (Figure 3F and Figure S3B). These obser-
vations suggest that S99Nmutationof FGF9causes impaired
chondrogenesis and aberrantly enhanced osteogenesis.
Diminished Activation of the MAPK as a Result
of FGF9 S99N Mutation
To explore the molecular mechanism by which
FGF9S99N causes impaired chondrocyte proliferation and09
Figure 4. Compromised Activation of
Erk1/2 and Wnt Signaling Pathways as
a Result of Decreased Receptor Binding
of FGF9S99N
(A) Loss of activation of Erk1/2 signaling
by FGF9S99N. NIH 3T3 cells treated with
the conditional medium for the indicated
time were lysed and subjected to western
blotting with the indicated antibodies.
Compared to WT FGF9, phosphorylation
of Erk1/2 and its downstream effector
p90RSK induced by FGF9S99N was signiﬁ-
cantly impaired.
(B) Abnormal activation of Wnt signaling
by FGF9S99N. RCJ cells were treated with
the same medium as in (A) for the indi-
cated time. Cell lysates were immunoblot-
ted with phospho-b-catenin, b-catenin,
c-Myc, and b-actin antibodies.
(C) Compromised receptor-binding
capacity of FGF9S99N. 293T cells were tran-
siently cotransfected with Fgfr3 and Flag-
FGF9 or Flag-FGF9S99N, or with Fgfr3 and
both at the indicated amount of expressing vectors. Cell lysates were immunoprecipitated with anti-Flag and then immunoblotted
with the indicated antibodies. Total cell lysates were included as input controls.
(D) FGF9S99N is able to form dimer with FGF9. 293T cells transiently transfected with Flag-FGF9, Flag-FGF9S99N, or empty vector were
lysed after 48 hr. The cell lysates and media were subjected to incubation with GST-FGF9 beads. The precipitates were immunoblotted
with Flag and GST antibodies. The quantitative analyses for all blots are shown as in Figure S5 on line.differentiation, we probed the signaling pathways down-
stream of the FGFR activation by using the PathScanMulti-
plex Western Cocktail I (Detection Kit #7100, New
England BioLab), which allows simultaneous detection of
Phospho-p90RSK, Phospho-Akt, Phospho-p44/42 MAPK,
and Phospho-S6 Ribosomal Proteins. Early passages of
NIH 3T3 cells, which express FGFR3, were used as target
cells to assess the activity of FGF9. Incubation of condi-
tioned medium collected from WT FGF9-expressing cells
was associated with elevated phosphorylation of p44/42
(ERK1/2) and p90RSK, but not Akt or S6 ribosomal protein
(data not shown). Given the fact that p90RSK is a down-
stream target of p44/42 MAPK, the result indicates that
binding of FGF9 to its receptor results in activation of the
MAPK pathway. With that, we compared FGF9S99N with
WT FGF9 for their ability to activate the MAPK pathway.
Incubation of the conditioned medium collected from
cells expressing S99N FGF9 mutant failed to simulate
p44/42 and p90RSK phosphorylation (Figure 4A), indi-
cating an inability of the FGF9 mutant to activate Erk1/2
signaling.
Impaired Wnt/b-Catenin Signaling Pathway
as a Result of S99N Mutation
WNTand FGF signaling pathways crosstalk during a variety
of cellular processes, such as human colorectal carcinogen-
esis, mouse mammary tumor virus (MMTV)-induced carci-
nogenesis, E2A-Pbx-induced leukemogenesis, early em-
bryogenesis, body-axis formation, limb-bud formation,
and neurogenesis.24 BothWNTand FGF signals downregu-
late GSK3b (GSK3B) activity, resulting in the stabilization
and the nuclear accumulation of b-catenin, which plays
a crucial role in multiple steps during chondrogenesisThand chondrocyte maturation.25 In light of the cross-talk
between the Wnt and FGF pathways, we further investi-
gated the effect of S99N mutation of FGF9 on the Wnt/b-
catenin signaling pathway. As expected, phosphorylation
of b-catenin (Ser33/37/Thr41) by GSK3b decreased when
RCJ cells were treated with WT FGF9 for 24 hr, and subse-
quently total b-catenin and its downstream target c-Myc
were signiﬁcantly induced. However, S99N mutation of
FGF9 attenuated b-catenin accumulation and c-Myc
expression, accompanied by an increase in phospho-b-cat-
enin level (Figure 4B), indicating an impaired ability of
FGF9 to activate the Wnt/b-catenin pathway because of
S99N mutation.
Compromised Binding of FGF9S99N to Its Receptor
To understand S99N mutation-associated deregulation of
cellular signaling, we examined the binding of this mutant
to its receptor, ﬁbroblast growth factor receptor 3 (FGFR3;
[MIM 134934]). 293T cells were transiently cotransfected
with Fgfr3 and Flag-FGF9 or Flag-FGF9S99N, or both con-
structs at a ratio of 1:1. Cell lysates were immunoprecipi-
tated with an anti-Flag antibody and blotted with an
anti-Fgfr3 antibody. Consistent with the prediction by
computer simulation (Figure 2E), S99N mutation causes
severe defects in receptor binding of FGF9, evidenced by
the ﬁnding that a signiﬁcantly decreased amount of Fgfr3
was immunoprecipitated from the lysate containing Flag-
FGF9S99N. Of note is the observation that the amount of
Fgfr3 precipitated from the lysate containing Flag-FGF9
and Flag-FGF9S99N (half of each) was in between WT and
mutant FGF9 alone (Figure 4C). The data indicates that
the FGF9 mutation leads to an impaired binding to its
receptor.e American Journal of Human Genetics 85, 53–63, July 10, 2009 59
Dimerization of FGF9S99N Itself or with WT FGF9
It has been well known that the formation of a ternary
complexbetween theFGF ligand, FGFR, andheparan sulfate
(HS) is crucial for FGF signaling. Previous work demon-
strated that ligand dimerization can signiﬁcantly enhance
the binding of FGF2 to FGFR1, the dimerization of the
receptor, and the induction of downstream signal-transduc-
tion pathways.26 We thus assessed the effect of S99Nmuta-
tion on FGF9 dimerization. GST-FGF9 on Sepharose beads
were subjected to incubation with either Flag-FGF9 or
Flag-FGF9S99N; Flag-tagged proteins precipitated by GST-
FGF9 were analyzed by immunoblotting. As shown in
Figure 4D, the amount ofWTFGF9or FGF9S99N precipitated
by GST-FGF9 Sepharose was comparable in the cell lysate
and medium. Furthermore, we performed a chemical
cross-linking assay, showing that FGF9S99N is able to form
dimer or tetramer as WT FGF9 does (Figure S4). These ﬁnd-
ings suggested that there was little effect of S99Nmutation
on the dimerization itself or with wild-type FGF9.
Discussion
SYNSwas ﬁrst reported byMaroteaux et al.,27 and thereafter
manyother designationswere used to describe this disorder,
including WL syndrome, symphalangism-brachydactyly
syndrome, deafness-symphalangism syndrome of Herr-
mann, and facioaudiosymphalangismsyndrome.28,29Avail-
able evidence indicates that the variation of clinical features
correlates with genetic heterogeneity in SYNS. Two disease-
causing genes, NOG and GDF5, have been identiﬁed to be
responsible for SYNS1 and SYNS2, respectively.30,31 SYNS1
is caused by a NOG mutation that usually displays synos-
toses at the elbow joint, proximal symphalangism, carpal
and tarsal fusion, and progressive conduction deafness.
Other features includeabroadhemicylindricalnosewithout
alar ﬂare and cervical vertebral fusions. SYNS2 resulting
from GDF5 mutation was ﬁrst described by Akarsu et al.31
and validated by Dawson et al.4 The major clinical features
were tarsal-carpal coalition, humeroradial synostoses, bra-
chydactyly, proximal symphalangism, a broad hemicylin-
drical nose, and vertebral fusion.However, conductive deaf-
ness usually does not appear. The patients harboring FGF9
S99N mutation in this large pedigree share most clinical
features with the SYNS cases reported previously, including
humeroradial synostoses or semidislocation at elbow joint,
synostosesof the interphalangeal joints, carpal fusionoccur-
ring at metacarpal and trapezium, tarsal fusion occurring
between cuneiform and navicular, and lumbar vertebral
fusion. It was noted that only mild semidislocation or cubi-
tus valgus at elbow joints, or limitation of ﬁnger joint
ﬂexion, was found in 4 patients at the age of 11 or below,
implicating that SYNS phenotype is age dependent. On
the basis of the facts that no mutations in either NOG or
GDF5 and the tight cosegregation of FGF9 S99N mutation
with SYNS phenotype were detected in this pedigree, we
believe that FGF9 couldbe a third locus for SYNSphenotype.60 The American Journal of Human Genetics 85, 53–63, July 10, 200It should be noted that the three different gene muta-
tions have been identiﬁed as SYNS disease-causative genes.
It may implicate that the mutant genes cause the disease
phenotype through a similar pathway or mechanism.
NOG encodes a secreted protein, Noggin, which was
shown to bind to BMP7 (MIM 112267) and inhibit BMP
signaling. The BMP binding afﬁnity of noggin variants is
highly correlated with alterations in bone formation and
apoptosis in chick limb development.32 It was also shown
that the requirement of Noggin during skeletogenesis
differs between species and between speciﬁc skeletal
elements within species.3 GDF5 is a secreted growth factor
expressed during several steps in skeletal development,
including the formation of the cartilage anlagen (chondro-
genesis), chondrocyte differentiation, and joint morpho-
genesis.33,34 A missense mutation (R438L) in GDF5 was re-
ported to be responsible for abnormal joint development,
although the mutant protein encoded by the SYNS allele
was secreted as a mature GDF5 dimer.4
FGF9 (glia-activating factor) belongs to the FGF super-
family, which consists of 22 members involved in various
developmental processes including the formation of meso-
derm during gastrulation, patterning during early postim-
plantation, and development of various tissues such as
limb, nervous, and skeletal systems in vertebrates.35,36
FGF9 was originally puriﬁed as a heparin-binding, secreted
glycoprotein from cultured human glioma cells.37Whereas
mutations in FGF9 were identiﬁed in 10 out of 203 tumor
tissues and cell lines,2 little is known about the association
of germline mutation of FGF9 with other human patholo-
gies. In fact, a similar phenotype to SYNS in a spontaneous
dominantmousemutant was reported previously, showing
elbow and knee joint synostosis (Eks).38 Most recently,
a missense mutation that replaces Asn143 with threonine
in the Fgf9 gene was identiﬁed in Eks mutant mice.39
Combined with these ﬁndings in mice, our data indicate
that mutations in FGF9, in addition to those in NOG and
GDF5, are responsible for SYNS.
FGF9 and its high-afﬁnity receptor FGFR3 had similar
developmental expression patterns, particularly in areas
of active chondrogenesis.40 Targeted overexpression of
FGF9 to cartilage of transgenic mice leads to reduced prolif-
eration and terminal differentiation of chondrocytes
similar to that observed in the human disorders, such as
achondroplasia and thanatophoricdysplasia causedbyacti-
vation mutations in FGFR3.40 Consistent with these ﬁnd-
ings, loss of Fgfr3 function in mice resulted in a phenotype
that is the opposite of that observed in achondroplasia and
thanatophoric dwarﬁsm.41,42 It was reported that Fgf9-deﬁ-
cient mice exhibited a disproportionate shortening of
proximal skeletal elements, which was a prominent feature
of patients with FGFR3-induced chondrodysplasia syn-
dromes, and that the Fgf9/ limb phenotype resulted
from loss of Fgf9 functions after formation of the mesen-
chymal condensation.18 These ﬁndings collectively suggest
that although the biological function of FGF9-FGFR3 may
vary with the gene dosage and developmental stage or cell9
types, FGFR3-mediated signaling plays an important role in
skeletal development. Of note, FGF9-associated SYNS
features multiple joint fusions, implicating a role for FGF9
in joint development. Together with the data derived
from mouse models, the compromised FGFR3 binding of
the FGF9 mutant found in SYNS patients suggests that an
adequate strength of FGF9-FGFR3 signaling is crucial for
normal skeletal and joint development.
It has been well documented that FGF signaling is
involved in multiple cellular processes, including cell
growth, differentiation, migration, and survival depending
on the cellular context.42 Three major intracellular path-
ways—ERK1/2, PI3K, and PLCg—have been shown to
mediate the activation of FGFRs.43 Among them, the ERK
pathway regulates cell proliferation, chondrocyte differen-
tiation, andsynthesisof extracellularmatrix components.44
We showed that in contrast to wild-type FGF9—which
through binding to FGFR345,46 induced a rapid increase in
phosphorylated ERK1/2 and consequently increased phos-
phorylation of its downstream effector, p90RSK—the ERK
pathway was not detectably stimulated by FGF9S99N, sug-
gesting a functional defect of the FGF9 mutant. Indeed,
biochemical analysis indicates that S99N mutation in
FGF9 resulted in an impaired FGFR3 binding, an outcome
predicted by computation simulation.
It was shown that conditional deletion of the b-catenin
gene in chondrocytes causes decreased chondrocyte prolif-
eration and delayed chondrocyte maturation,47 and over-
expression of inhibitor of b-catenin and TCF (ICAT) in
chondrocytes resulted in suppression of chondrocyte pro-
liferation and differentiation in transgenic mice.48 We
showed that the FGF9 mutation resulted in an increased
phospho-b-catenin level and subsequently deregulated
expression of b-catenin and c-Myc, consistent with the
active cross-talk betweenWnt and FGF signaling pathways
that has been shown to take place during a variety of
cellular processes.
Taken together, our data indicate that as a result of the
S99N mutation, the ability of FGF9 to bind its receptor is
severely impaired, leading to the defective ERK signaling
and deregulated WNT/b-catenin pathways. Cell-signaling
abnormalities due to FGF9 S99N mutation result in an
impaired chondrogenesis and aberrantly enhanced osteo-
genesis, leading to joint fusions during development.
Thus, we demonstrate, for the ﬁrst time, that S99N muta-
tion in FGF9 is the third cause of SYNS, implicating
a crucial role of FGF9 in human joint development.
Supplemental Data
Supplemental Data include a list of primers, ﬁve ﬁgures, and one
table and can be found with this article online at http://www.
ajhg.org/.
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